<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Korean J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">KJO</journal-id>
      <journal-title-group>
        <journal-title>Korean Journal of Ophthalmology : KJO</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8942</issn>
      <publisher>
        <publisher-name>The Korean Ophthalmological Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19568365</article-id>
      <article-id pub-id-type="pmc">2694291</article-id>
      <article-id pub-id-type="doi">10.3341/kjo.2009.23.2.124</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Serous Retinal Detachment Following Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Eui Yon</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jong Wan</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jun Bum</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lew</surname>
            <given-names>Ho Min</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.</aff>
      <author-notes>
        <corresp>Reprint requests to Ho Min Lew, MD. Department of Ophthalmology, Ajou University School of Medicine, San 5, Wonchon-dong, Youngtong-gu, Suwon 443-721, Korea. Tel: 82-31-219-5673, Fax: 82-31-219-5259, <email>hmlew@ajou.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>6</month>
        <year>2009</year>
      </pub-date>
      <volume>23</volume>
      <issue>2</issue>
      <fpage>124</fpage>
      <lpage>126</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>7</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>4</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2009 by the Korean Ophthalmological Society</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report a case of serous retinal detachment following combined photodynamic therapy (PDT) and intravitreal bevacizumab injection in subfoveal choroidal neovascularization (CNV).</p>
        <p>A 53-year-old woman was diagnosed with subfoveal CNV secondary to age-related macular degeneration (AMD) and treated with combined PDT and intravitreal bevacizumab injection. One day after treatment, the patient experienced a sudden decline of vision and optical coherence tomography (OCT) showed serous retinal detachment involving the macula. She was managed conservatively with an oral steroid beginning on the second day of the combined treatment and the subretinal fluid started to decrease one week following the initiation of steroids.</p>
        <p>This case suggests that combined PDT and intravitreal injection of bevacizumab can be associated with serous retinal detachment. Additional studies are needed to establish the safety and complications following this treatment regimen.</p>
      </abstract>
      <kwd-group>
        <kwd>Intravitreal bevacizumab injection</kwd>
        <kwd>Photodynamic therapy</kwd>
        <kwd>Serous retinal detachment</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Intravitreal bevacizumab injection and photodynamic therapy (PDT) with Verteporfin are effective for the treatment of choroidal neovascularization (CNV).<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> Recently, combined PDT with Verteporfin and intravitreal bevacizumab injection has shown a synergistic effect and might reduce the need for retreatment and cyclic injections of bevacizumab.<xref ref-type="bibr" rid="B3">3</xref></p>
    <p>Single treatments of PDT and intravitral bevacizumab injection are considered relatively safe and effective.<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref> However, PDT may cause visual disturbances, subretinal hemorrhage, suprachoroidal hemorrhage and retinal pigment epithelial tear, and there are reported complications following intravitreal bevacizumab injection such as retinal pigment epithelial tear and acute glaucoma.<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B11">11</xref></p>
    <p>Chung et al.<xref ref-type="bibr" rid="B12">12</xref> reported a case of retinal detachment with macular hole following combined PDT and intravitreal bevacizumab injection but the safety of combined treatment with these two modalitiesis not well established.</p>
    <p>We herein present a case of serous retinal detachment after combined PDT and intravtreal bevacizumab injection in subfoveal CNV.</p>
    <sec sec-type="cases">
      <title>Case Report</title>
      <p>A 53-year-old woman presented with metamorphopsia in her right eye. She was diagnosed with subfoveal CNV secondary to age-related macular degeneration (AMD) and the best-corrected visual acuity of the right eye was 20/50. PDT with Verteporfin was performed according to the standard protocol of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Investigation and repeated after 5 months.<xref ref-type="bibr" rid="B13">13</xref> The visual acuity of the involved eye did not change.</p>
      <p>Fifteen months after the second PDT, fluorescein angiography of the affected eye revealed persistent subfoveal CNV and the best corrected visual acuity remained 20/50 (<xref ref-type="fig" rid="F1">Fig. 1A</xref>, <xref ref-type="fig" rid="F2">2A</xref>). Combined PDT according to the same standard protocol and 1.25 mg intravitreal bevacizumab injection was performed on the same day. One day after the treatment, the patient's vision had decreased to counting fingers. Fundus examination and optical coherence tomography (OCT) showed serous retinal detachment involving the macula (<xref ref-type="fig" rid="F2">Fig. 2B</xref>).</p>
      <p>On post-treatmentday two, the patient was initiated on an oral steroid (Triamcinolone&#xAE; 24 mg #1) to complete a two week course. One week into steroid therapy, the visual acuity remained the same, but OCT findings of the right eye showed decreased serous retinal detachment (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). The vision slightly improved to 20/200 upon completion of the two week steroid course and fluorescein angiography showed decreased leakage of fluorescein dye (<xref ref-type="fig" rid="F1">Fig. 1B</xref>).</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>There have been several reports about serous retinal detachment after PDT treatment.<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B14">14</xref> Mennel et al.<xref ref-type="bibr" rid="B7">7</xref> quantified transient serous retinal detachment in CNV after PDT using OCT. Kim et al.<xref ref-type="bibr" rid="B9">9</xref> also suggested that serous retinal detachment might develop following PDT but might also resolve spontaneously several days following treatment. However, there is neither a published report of serous retinal detachment after the combined use of PDT and intravitreal bevacizumab injection nor following intravitreal bevacizumab injection alone.</p>
      <p>Several mechanisms may be responsible for subretinal fluid accumulation after combined treatment with PDT and intravitreal bevacizumab injection. The PDT may induce fluid leakage from the CNV itself or damage of retinal pigment epithelium causing an alteration of the blood-retinal barrier.<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref> Bevacizumab may cause instability of the intraretinal and subretinal fluid and subsequent serous retinal detachment by rapidly modulating the permeability and activity of the CNV.<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref></p>
      <p>In our patient, there was no evidence of increased subretinal fluid after the first two treatments of PDT alone and the PDT protocol was the same for all three treatments. Occurrence of the serous retinal detachment just after combined PDT and intravitreal bevacizumab injection suggests the interaction of these two modalities as a possible causal role. However, the definitive causation of serous retinal detachment in PDT alone, intravitreal bevacizumab injection alone or combined treatment cannot be determined.</p>
      <p>A two week course of oral steroids was used to manage the serous retinal detachment after the combined treatment of PDT and intravitreal bevacizumab injection. The acute inflammatory reaction following either modality may be relieved by systemic steroids. Kim et al.<xref ref-type="bibr" rid="B9">9</xref> injected Triamcinolone&#xAE; into the vitreous in a patient with serous retinal detachment following PDT, whereas, we elected to use a more conservative management with an oral steroid.</p>
      <p>In conclusion, combined PDT and intravitreal bevacizumab injection can be associated with serous retinal detachment which may cause sudden visual loss. Additional studies are needed to establish the standard protocol, safety and complications regarding the combined treatment of PDT and intravitreal bevacizumab injection.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Boo</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>Result of photodynamic therapy for idiopathic subfoveal choroidal neovascuarization</article-title>
          <source>Korean J Ophthalmol</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>264</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="pmid">16491815</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avery</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Pieramici</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Pieramici</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration</article-title>
          <source>Ophthalmology</source>
          <year>2006</year>
          <volume>113</volume>
          <fpage>363</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">16458968</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhalla</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Blinder</surname>
              <given-names>KJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in are-related macular degeneration</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>988</fpage>
          <lpage>993</lpage>
          <pub-id pub-id-type="pmid">17151484</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fung</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Reichel</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The international intravitreal Bevacizumab safty survey: using the internet to assess drug safety worldwide</article-title>
          <source>Br J Ophthalmol</source>
          <year>2006</year>
          <volume>90</volume>
          <fpage>1344</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">16854824</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rich</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Puliafito</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Short-term safety and efficacy of intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>495</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="pmid">16770255</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt-Erfurth</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Sickenberg</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study</article-title>
          <source>Arch Ophthalmol</source>
          <year>1999</year>
          <volume>117</volume>
          <fpage>1177</fpage>
          <lpage>1187</lpage>
          <pub-id pub-id-type="pmid">10496389</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mennel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Eggarter</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy</article-title>
          <source>Am J Ophthalmol</source>
          <year>2005</year>
          <volume>140</volume>
          <fpage>758</fpage>
          <lpage>760</lpage>
          <pub-id pub-id-type="pmid">16226542</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gelisken</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Inhoffen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Partsch</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization</article-title>
          <source>Am J Ophthalmol</source>
          <year>2001</year>
          <volume>131</volume>
          <fpage>518</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="pmid">11292425</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heo</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Serous retinal detachment in patients with choroidal neovascularization following photodynamic therapy</article-title>
          <source>J Korean Ophthalmol Soc</source>
          <year>2007</year>
          <volume>48</volume>
          <fpage>1354</fpage>
          <lpage>1361</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>SJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Retinal pigment epithelial tear after intravitreal bevacizumab injection</article-title>
          <source>Am J Ophthalmol</source>
          <year>2006</year>
          <volume>142</volume>
          <fpage>1070</fpage>
          <lpage>1072</lpage>
          <pub-id pub-id-type="pmid">17157598</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jalil</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fenerty</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Charles</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication</article-title>
          <source>Eye</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1541</fpage>
          <pub-id pub-id-type="pmid">17962821</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection</article-title>
          <source>Korean J Ophthalmol</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>185</fpage>
          <lpage>187</lpage>
          <pub-id pub-id-type="pmid">17804928</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <collab>Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group</collab>
          <article-title>Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials--TAP report</article-title>
          <source>Arch Ophthalmol</source>
          <year>1999</year>
          <volume>117</volume>
          <fpage>1329</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="pmid">10532441</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Farah</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Cardillo</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization</article-title>
          <source>Retina</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>159</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">12707593</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>(A) Fundoscopic photography and fluorescein angiography showing leakage of fluorescein dye consistent with subfoveal choroidal neovascularization (CNV) before combined photodynamic therapy (PDT) and intravtreal bevacizumab injection. (B) Leakage of fluorescein dye decreased two weeks after the combined PDT and intravtreal bevacizumab injection.</p>
      </caption>
      <graphic xlink:href="kjo-23-124-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Optical coherence tomography (OCT) before and after the combined photodynamic therapy (PDT) and intravtreal bevacizumab injection. (A) Before combined PDT and intravtreal bevacizumab injection, OCT image demonstrates a minimally hyporeflective area in the subneuroretinal space. (B) One day after the combined treatment, OCT image reveals significant enlargement of the hyporeflective area, representing the amount of fluid accumulation. (C) One week after taking the oral steroid, the subretinal fluid has absorbed nearly completely, similar to pretreatment OCT findings.</p>
      </caption>
      <graphic xlink:href="kjo-23-124-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
